19.58
-0.1(-0.51%)
Currency In USD
| Previous Close | 19.68 |
| Open | 19.46 |
| Day High | 20.02 |
| Day Low | 18.51 |
| 52-Week High | 41.31 |
| 52-Week Low | 12.21 |
| Volume | 546,431 |
| Average Volume | 1.02M |
| Market Cap | 600.46M |
| PE | -3.82 |
| EPS | -5.12 |
| Moving Average 50 Days | 18.37 |
| Moving Average 200 Days | 24.19 |
| Change | -0.1 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $1,151.76 as of May 09, 2025 at a share price of $19.58. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $982.93 as of May 09, 2025 at a share price of $19.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Stock Repurchase Plan
GlobeNewswire Inc.
Mar 24, 2025 1:15 PM GMT
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repur
Anaptys Announces Participation in March Investor Conferences
GlobeNewswire Inc.
Feb 27, 2025 9:15 PM GMT
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
GlobeNewswire Inc.
Feb 11, 2025 10:30 PM GMT
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from